• Publications
  • Influence
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.
BACKGROUND Multiple myeloma is a progressive cancer for which there is no cure. Despite treatment, almost all patients eventually experience periods of disease relapse and remission. With theExpand
  • 30
  • 4
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Busulfan, a highly effective and established drug for treating polycythemia vera (PV) produces lasting clinical and hematologic responses.[1][1] The frequency of its use as therapy for PV hasExpand
  • 26
  • 3
Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera
Background Although reduction in the JAK2V617F allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as aExpand
  • 24
  • 2
  • PDF
Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
BACKGROUND Multiple myeloma is an incurable B-cell malignancy with a natural history that involves alternating periods of remission and subsequent relapse. For relapsed and/or refractory multipleExpand
  • 4
  • 2
Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
ABSTRACT Background: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. Methods: Using retrospectiveExpand
  • 25
  • 1
The JAK2V617F Mutation Seen in Myeloproliferative Neoplasms (MPNs) Occurs in Patients with Inflammatory Bowel Disease: Implications of a Pilot Study
Patients with IBD frequently have hematologic abnormalities suggestive of JAK2 mutated MPNs, but are traditionally classified as reactive processes. Haplotype 46/1 is a well-characterized geneticExpand
  • 5
  • 1
  • PDF
Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advancedTP53wt acute leukemias
Background: NVP-HDM201 is a selective inhibitor of the p53-HDM2 interaction and has demonstrated potent single-agent activity in various in vitro and in vivo tumor models, dependent on wild-type (wt)Expand
  • 4
  • 1
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
BACKGROUND Thirty consecutive patients underwent hematopoietic stem cell transplantation for myelofibrosis (MF) at our institution. The median age at the time of transplant was 49 (range, 18-68)Expand
  • 11
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Activation of p53 by inhibitors of the p53-MDM2 interaction is being pursued as a therapeutic strategy in p53 wild-type cancers. Here, we report distinct mechanisms by which the novel, potent, andExpand
  • 16